title: Clinical utility of maraviroc.
abstract: Maraviroc belongs to the family of chemokine (C-C motif) receptor 5 (CCR5) antagonists that prevent the entry of human immunodeficiency virus (HIV) into host CD4+ T cells by blocking the CCR5 co-receptor R5. Maraviroc is currently the only CC5R co-receptor inhibitor that has been approved for clinical use in HIV-1-infected patients carrying the CCR5 tropism who are antiretroviral-naïve or have experienced therapeutic failure following traditional antiretroviral therapies. This article is a review of the main characteristics of maraviroc and the latest data regarding its clinical application. Maraviroc is effective and well tolerated in pre-treated and antiretroviral-naïve patients with HIV-1 infections carrying the CCR5 tropism. Data from the phase III programme of maraviroc, which includes the MOTIVATE 1 and 2 studies and the MERIT study, indicate that maraviroc significantly (p < 0.001) increases CD4+ cell counts compared with placebo in pre-treated patients and to a similar extent as efavirenz in antiretroviral-naïve patients. Even in cases where viral load is not completely suppressed, maraviroc improves immunological response compared with placebo. In addition, promising research suggests that maraviroc has favourable pharmacokinetic and safety profiles in patients with high cardiovascular risk or those co-infected with tuberculosis or hepatitis and could be considered an option for treatment of HIV-infected patients with these co-morbidities. Resistance to maraviroc is low and mainly related to the presence of chemokine (C-X-C motif) receptor 4 (CXCR4) tropism HIV-1-infections or to mutations in the V3 region of glycoprotein (gp) 120; however, the exact mechanisms by which resistance is acquired and their genotypic and phenotypic pattern have not yet been established. It is recommended that a tropism test should be performed when considering maraviroc as an alternate drug in HIV-1-infected patients. Current tropism assays have increased sensitivity to reliably detect CXCR4 HIV with rapid turn-around and at a low cost. Improved detection together with positive data on the drug's efficacy and safety profiles should help physicians to identify more accurately the appropriate candidates for commencement of treatment with maraviroc. In summary, maraviroc improves immunological response and has shown favourable pharmacokinetic and safety profiles in patients with high cardiovascular risk or in those co-infected with tuberculosis or hepatitis. Long-term studies are needed to confirm whether therapeutic expectations resulting from clinical trials with maraviroc translate into a real benefit for HIV-1-infected patients for whom traditional antiretroviral therapies have failed or are not suitable.
authors: Hospital Virgen de las Nieves, Granada, Spain.
authors: Jorge
authors: J
authors: Parra
authors: Hospital General de Alicante, Alicante, Spain.
authors: Joaquín
authors: J
authors: Portilla
authors: Hospital 12 de Octubre, Madrid, Spain. federicopulido@med.ucm.es.
authors: Federico
authors: F
authors: Pulido
authors: Unidad Médica, Pfizer España, Madrid, Spain.
authors: Rainel
authors: R
authors: Sánchez-de la Rosa
authors: Hospital Son Llàtzer de Palma de Mallorca (IUNICS-INM), Palma de Mallorca, Spain.
authors: Carlos
authors: C
authors: Alonso-Villaverde
authors: Hospital Gregorio Marañón, Madrid, Spain.
authors: Juan
authors: J
authors: Berenguer
authors: Hospital CLINIC, Barcelona, Spain.
authors: José L
authors: JL
authors: Blanco
authors: Hospital Sant Pau, Barcelona, Spain.
authors: Pere
authors: P
authors: Domingo
authors: Hospital Ramón y Cajal, Madrid, Spain.
authors: Fernando
authors: F
authors: Dronda
authors: Hospital Virgen de la Arrixaca, Murcia, Spain.
authors: Carlos
authors: C
authors: Galera
authors: Hospital General Universitario de Elche, Alicante, Spain.
authors: Félix
authors: F
authors: Gutiérrez
authors: Hospital Reina Sofía, Cordoba, Spain.
authors: José M
authors: JM
authors: Kindelán
authors: Hospital del Mar, Barcelona, Spain.
authors: Hernando
authors: H
authors: Knobel
authors: Hospital Virgen del Rocío, Seville, Spain.
authors: Manuel
authors: M
authors: Leal
authors: Hospital La Fe, Valencia, Spain.
authors: Jose
authors: J
authors: López-Aldeguer
authors: Hospital Arquitecto Mancide, Ferrol, Spain.
authors: Ana
authors: A
authors: Mariño
authors: Complejo Universitario de Vigo, Pontevedra, Spain.
authors: Celia
authors: C
authors: Miralles
authors: Hospital Germans Trials i Pujol, Badalona, Spain.
authors: José
authors: J
authors: Moltó
authors: Hospital General del Valencia, Valencia, Spain.
authors: Enrique
authors: E
authors: Ortega
authors: Hospital San Pedro-CIBIR, La Rioja, Spain.
authors: José A
authors: JA
authors: Oteo
references: Curr Opin Immunol. 2005 Aug;17(4):366-73
references: 15955686
references: J Acquir Immune Defic Syndr. 2008 Sep 1;49 Suppl 2:S79-85
references: 18725816
references: Arterioscler Thromb Vasc Biol. 2005 Dec;25(12):2642-7
references: 16239591
references: Br J Clin Pharmacol. 2010 Jan;69(1):51-7
references: 20078612
references: Curr Med Chem. 2006;13(8):911-34
references: 16611075
references: Clin Infect Dis. 2000 May;30(5):779-83
references: 10816148
references: Science. 1996 Jun 28;272(5270):1955-8
references: 8658171
references: AIDS. 1998 May 7;12(7):F51-8
references: 9619798
references: Expert Opin Drug Saf. 2008 Sep;7(5):559-69
references: 18759708
references: Br J Clin Pharmacol. 2008 Apr;65 Suppl 1:47-53
references: 18333865
references: Atherosclerosis. 2007 Nov;195(1):e92-103
references: 17466311
references: MMWR Morb Mortal Wkly Rep. 2000 Mar 10;49(9):185-9
references: 11795500
references: J Infect Dis. 2005 Aug 1;192(3):466-74
references: 15995960
references: Genes Immun. 2001 Jun;2(4):191-5
references: 11477473
references: AIDS Res Hum Retroviruses. 2004 Jan;20(1):111-26
references: 15000703
references: Antivir Ther. 2009;14(5):607-18
references: 19704163
references: Br J Clin Pharmacol. 2008 Apr;65 Suppl 1:5-18
references: 18333861
references: Br J Clin Pharmacol. 2008 Apr;65 Suppl 1:38-46
references: 18333864
references: J Antimicrob Chemother. 2009 Oct;64(4):845-9
references: 19671585
references: Br J Clin Pharmacol. 2008 Apr;65 Suppl 1:19-26
references: 18333862
references: Br J Clin Pharmacol. 2008 Apr;65 Suppl 1:86-94
references: 18333870
references: AIDS. 2006 Jun 26;20(10):1359-67
references: 16791010
references: Hepatology. 2003 Dec;38(6):1468-76
references: 14647058
references: Enferm Infecc Microbiol Clin. 2008 Jun-Jul;26(6):356-79
references: 18588819
references: N Engl J Med. 2008 Oct 2;359(14):1429-41
references: 18832244
references: Cell. 1996 Aug 9;86(3):367-77
references: 8756719
references: Antimicrob Agents Chemother. 2005 Nov;49(11):4721-32
references: 16251317
references: Medicina (B Aires). 2005;65(4):353-60
references: 16193718
references: N Engl J Med. 2005 Jan 6;352(1):48-62
references: 15635112
references: Curr HIV Res. 2005 Jul;3(3):243-59
references: 16022656
references: Atherosclerosis. 2001 Sep;158(1):233-9
references: 11500196
references: Nat Med. 2005 Nov;11(11):1170-2
references: 16205738
references: AIDS. 2009 Nov 27;23(18):2377-85
references: 19834318
references: Invest Ophthalmol Vis Sci. 1998 Nov;39(12):2417-26
references: 9804150
references: Antimicrob Agents Chemother. 2008 Mar;52(3):858-65
references: 18070967
references: J Virol. 2006 May;80(10):4909-20
references: 16641282
references: Nature. 1996 Jun 20;381(6584):661-6
references: 8649511
references: J Antimicrob Chemother. 2010 Jul;65(7):1493-6
references: 20488982
references: Mucosal Immunol. 2008 Jan;1(1):23-30
references: 19079157
references: AIDS. 2007 Sep 12;21(14):F17-24
references: 17721088
references: Am J Respir Crit Care Med. 2003 Feb 15;167(4):603-62
references: 12588714
references: Int J Tuberc Lung Dis. 2005 Mar;9(3):248-57
references: 15786886
references: Int J STD AIDS. 2009 May;20(5):339-45
references: 19386972
references: Tuber Lung Dis. 1994 Oct;75(5):341-7
references: 7841427
references: Int J Clin Pharmacol Ther. 2011 Feb;49(2):162-8
references: 21255533
references: Nature. 1998 Jan 15;391(6664):240
references: 9440686
references: J Biol Chem. 2000 Feb 25;275(8):5466-71
references: 10681524
references: Nature. 1996 Aug 22;382(6593):722-5
references: 8751444
references: Br J Clin Pharmacol. 2008 Apr;65 Suppl 1:68-75
references: 18333868
references: Clin Infect Dis. 2008 Jul 15;47(2):236-41
references: 18532888
references: Circ Res. 2004 Feb 6;94(2):253-61
references: 14656931
references: J Virol. 2007 Jan;81(2):441-5
references: 17079285
references: J Virol. 2007 Mar;81(5):2359-71
references: 17182681
references: Eur J Med Res. 2007 Oct 15;12(9):409-17
references: 17933722